Navigation Links
Echosens: Launch of the FibroScan®502 Touch
Date:10/27/2011

PARIS, October 27, 2011 /PRNewswire/ --

Since its initial inception, Echosens has a history of innovation and it continues to widen and strengthen its product range with the recent introduction of the FibroScan® 502 Touch.

Equipped with a new and more ergonomic tactile interface, and based on patented Vibration-Controlled Transient Elastography (VCTE™), the latest FibroScan® provides a reliable, accurate and reproducible assessment of liver tissue stiffness.

This patented VCTE technology, developed by Echosens, is unique in measuring liver stiffness at a pre-determined and controlled 50 Hz frequency.

The FibroScan® 502 Touch offers enhanced patient data management with more complete and personalized exam reports. Compatible with the complete range of FibroScan probes (S+, M+ and XL+) it offers simultaneous connection of 2 probes giving flexibility for the patient assessment.  An indicator recommends the probe best suited to the patient's morphology.

Echosens' FS 502 Touch represents a quicker and more complete device built around the latest generation of electronics.

Continuing Echosens' history of innovation, the FS 502 Touch is further enhanced by the optional integration of the latest technological innovation: CAP™ (Controlled Attenuation Parameter), the new parameter for steatosis assessment and quantification.

Echosens has also launched new software for managing FibroScan® examinations: the Desk Solution. This comprehensive and innovative solution provides ready access to FibroScan assessments on the physician's desk-top PC.

Echosens products are widely available in most global markets and the company is actively pursuing the necessary FDA approvals to homologate its devices for sale in the United States.

About Echosens and Fibroscan®

FibroScan® is designed to quantify hepatic elasticity and steatosis in a non-invasive manner in chronic liver diseases assessment.

Founded in 2001, Echosens supplies its products in more than 70 countries through a global network of suppliers. It dedicates a major portion of its activity to research and development in order to invent new medical devices and open up new medical perspectives.  The organization works in close cooperation with health professionals and patients' associations to facilitate management and therapeutic monitoring of patients.  To date, there around 400 publications which attest to the efficacy of FibroScan in clinical practice.

Press Contact

ECHOSENS
Richard GUILLAUME
contact@echosens.com
+33-144-827850

 


'/>"/>
SOURCE Echosens
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. nContact, Inc. Launches New Corporate Websites
2. First Response Launches IVF Fundraising Resource for Those Trying for a Baby
3. Latest Pharmaceutical Launch Strategies Demonstrate Growing Importance of Thought Leader Engagement at Market Entry
4. CDC Launches Effort to Protect Cancer Patients From Infections
5. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
6. Gamma Pharmaceuticals, Inc., Launches Retail Promotions for Gamma Energy Gel™ in New York City and Houston
7. Recent Research Provides Formula for Timely Product Launch: Good Science + Effective FDA Relations
8. Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology
9. Arthrosurface Launches Worlds First Talus Resurfacing Implant for the Ankle
10. Medical Alarm and Harrington Multi Media Schedule Production for MediPendant™ National Television Launch
11. DYMO® Labeling Launches High-Resolution Identification Scanner for Health Records Processing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017   Royal Philips (NYSE: ... technology, and PathAI, a company that develops artificial ... aim to develop solutions that improve the precision ... other diseases. The partnership aims to build deep ... of artificial intelligence to be applied to massive ...
(Date:3/29/2017)... 2017 Neurim Pharmaceuticals ("Neurim") and ... exclusive marketing rights for Neurim,s new Rx PedPRM in ... ... sleep disorders in children with Autism Spectrum Disorders (ASD) and neurogenetic ... for children. The collaboration with Exeltis will help increase ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... to their offering. ... The global patient safety and risk management software market is ... Patient safety has become a priority for almost all ... in the last decade and is currently on the verge of ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of the most ... touted to be the next revolution in our fight against this complex disease. One ... of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few ...
(Date:3/29/2017)... (PRWEB) , ... March 29, ... ... suburbs and South Hills of Pittsburgh now have easier access to the ... only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of ... Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over ... recently, the only option for on-premises installation of its Help System for SharePoint was ... install the system into the entire tenant. , The company recently released a ...
(Date:3/28/2017)... ... ... Tuesday, March 28, 2017, is the annual American Diabetes Association Alert Day, ... find out if they are at risk for developing Type 2 diabetes. In recognition ... by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower Crown Lights ...
Breaking Medicine News(10 mins):